- Home
- EVAX vs ONCO Comparison
EVAX vs ONCO Comparison
Compare EVAX & ONCO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- EVAX
- ONCO
- Stock Information
- Founded
- EVAX 2008
- ONCO 2018
- Country
- EVAX Denmark
- ONCO United States
- Employees
- EVAX N/A
- ONCO N/A
- Industry
- EVAX Biotechnology: Biological Products (No Diagnostic Substances)
- ONCO Biotechnology: Pharmaceutical Preparations
- Sector
- EVAX Health Care
- ONCO Health Care
- Exchange
- EVAX Nasdaq
- ONCO Nasdaq
- Market Cap
- EVAX 16.3M
- ONCO 3.6M
- IPO Year
- EVAX 2021
- ONCO 2022
- Fundamental
- Price
- EVAX $1.79
- ONCO $0.13
- Analyst Decision
- EVAX Strong Buy
- ONCO
- Analyst Count
- EVAX 3
- ONCO 0
- Target Price
- EVAX $33.33
- ONCO N/A
- AVG Volume (30 Days)
- EVAX 211.9K
- ONCO 2.1M
- Earning Date
- EVAX 03-26-2025
- ONCO 04-10-2025
- Dividend Yield
- EVAX N/A
- ONCO N/A
- EPS Growth
- EVAX N/A
- ONCO N/A
- EPS
- EVAX N/A
- ONCO N/A
- Revenue
- EVAX $3,295,000.00
- ONCO $1,870,605.00
- Revenue This Year
- EVAX $9,039.73
- ONCO N/A
- Revenue Next Year
- EVAX $1.47
- ONCO N/A
- P/E Ratio
- EVAX N/A
- ONCO N/A
- Revenue Growth
- EVAX N/A
- ONCO N/A
- 52 Week Low
- EVAX $1.70
- ONCO $0.13
- 52 Week High
- EVAX $22.05
- ONCO $21.40
- Technical
- Relative Strength Index (RSI)
- EVAX 35.07
- ONCO 18.44
- Support Level
- EVAX $1.75
- ONCO $0.16
- Resistance Level
- EVAX $1.99
- ONCO $0.25
- Average True Range (ATR)
- EVAX 0.17
- ONCO 0.03
- MACD
- EVAX 0.05
- ONCO -0.01
- Stochastic Oscillator
- EVAX 10.70
- ONCO 1.56
About EVAX Evaxion Biotech
Evaxion Biotech AS is a clinical-stage biotech company that aspires to the exploration of artificial intelligence, or AI, to develop immunotherapies with improved efficacy when compared to currently marketed products for patients with unmet medical needs. Its pipeline programs are derived from its proprietary AI platforms, PIONEER, EDEN, RAVEN, and ObsERV. The company is utilizing these AI platforms to build a drug development pipeline. Its product candidates are; EVX-01 and EVX-02, for the treatment of various cancers, and the third candidate is cancer immunotherapy, EVX-03, for the treatment of various cancers including non-small-cell-lung-cancer, or NSCLC, is in pre-clinical development.
About ONCO Onconetix Inc.
Onconetix Inc is a commercial-stage biotechnology company focused on the research, development, and commercialization of innovative solutions for men's health and oncology. It has a product named Entadfi an FDA-approved once-daily oral therapeutic for the treatment of benign prostatic hyperplasia, a disorder of the prostate, along with building additional assets in therapeutics, diagnostics, and clinician services for oncology.